Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
FATE

FATE - Fate Therapeutics Inc Stock Price, Fair Value and News

4.28USD-0.03 (-0.70%)Market Closed

Market Summary

FATE
USD4.28-0.03
Market Closed
-0.70%

FATE Stock Price

View Fullscreen

FATE RSI Chart

FATE Valuation

Market Cap

487.2M

Price/Earnings (Trailing)

-2.56

Price/Sales (Trailing)

8.01

Price/Free Cashflow

-3.49

FATE Price/Sales (Trailing)

FATE Profitability

Return on Equity

-44.6%

Return on Assets

-33.35%

Free Cashflow Yield

-28.69%

FATE Fundamentals

FATE Revenue

Revenue (TTM)

63.5M

Rev. Growth (Yr)

-96.22%

Rev. Growth (Qtr)

-13.79%

FATE Earnings

Earnings (TTM)

-190.1M

Earnings Growth (Yr)

-154.25%

Earnings Growth (Qtr)

-8.8%

Breaking Down FATE Revenue

Last 7 days

18.6%

Last 30 days

25.5%

Last 90 days

-10.6%

Trailing 12 Months

-3.8%

How does FATE drawdown profile look like?

FATE Financial Health

Current Ratio

8.69

Debt/Equity

0.02

Debt/Cashflow

-14.44

FATE Investor Care

Shares Dilution (1Y)

15.70%

Diluted EPS (TTM)

-1.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023136.9M119.3M106.2M63.5M
202263.1M68.3M69.0M96.3M
202140.1M48.0M54.7M55.8M
202010.6M13.2M18.3M31.4M
20196.3M8.1M9.5M10.7M
20184.1M4.1M4.1M4.7M
20174.1M4.1M4.1M4.1M
20163.8M4.5M4.5M4.4M
20150828.0K1.6M2.4M
20132.7M1.9M1.6M971.0K
20121.5M1.9M2.3M2.7M
20110001.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Fate Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 04, 2024
dulac edward j iii
sold
-19,013
7.77
-2,447
chief financial officer
Jan 29, 2024
dulac edward j iii
sold
-9,245
5.00
-1,849
chief financial officer
Jan 09, 2024
tahl cindy
sold
-47,519
4.37
-10,874
general counsel and secretary
Jan 09, 2024
valamehr bahram
sold
-49,367
4.38
-11,271
chief r&d officer
Jan 09, 2024
wolchko j scott
sold
-62,888
4.37
-14,391
president and ceo
Jan 09, 2024
dulac edward j iii
sold
-30,712
4.37
-7,028
chief financial officer
Jan 02, 2024
dulac edward j iii
sold
-18,966
3.66
-5,182
chief financial officer
Dec 26, 2023
redmile group, llc
bought
166,024
3.72
44,630
-
Dec 26, 2023
redmile group, llc
sold
-6,157,980
3.72
-1,655,370
-
Dec 18, 2023
dulac edward j iii
sold
-5,547
3.5
-1,585
chief financial officer

1–10 of 50

Which funds bought or sold FATE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
2.13
-68,379
57,407
-%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
sold off
-100
-161,766
-
-%
Jul 18, 2024
Blue Trust, Inc.
new
-
294
294
-%
Jul 18, 2024
Assenagon Asset Management S.A.
added
1.04
-10,259,500
8,445,030
0.02%
Jul 17, 2024
Leo Wealth, LLC
new
-
34,240
34,240
-%
Jul 12, 2024
SG Americas Securities, LLC
reduced
-2.89
-156,000
119,000
-%
Jul 10, 2024
Hilltop National Bank
unchanged
-
-1,157
935
-%
Jul 10, 2024
Simplicity Wealth,LLC
added
3.66
-43,403
37,454
-%
Jul 10, 2024
ALBION FINANCIAL GROUP /UT
unchanged
-
-914
738
-%
Jul 10, 2024
EPIQ PARTNERS, LLC
sold off
-100
-73,921
-
-%

1–10 of 49

Are Funds Buying or Selling FATE?

Are funds buying FATE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FATE
No. of Funds

Unveiling Fate Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 25, 2024
redmile group, llc
14.9%
17,619,095
SC 13D/A
Feb 13, 2024
vanguard group inc
9.43%
9,293,363
SC 13G/A
Feb 12, 2024
boxer capital, llc
6.3%
6,171,000
SC 13G
Feb 09, 2024
capital world investors
0.0%
0
SC 13G/A
Jan 25, 2024
point72 asset management, l.p.
4.8%
4,730,700
SC 13G
Jan 24, 2024
blackrock inc.
11.4%
11,212,816
SC 13G/A
Jan 22, 2024
state street corp
1.89%
1,861,919
SC 13G/A
Dec 28, 2023
redmile group, llc
14.9%
15,049,839
SC 13D/A
Oct 10, 2023
state street corp
2.31%
2,271,925
SC 13G/A
May 10, 2023
state street corp
14.24%
13,989,432
SC 13G/A

Recent SEC filings of Fate Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
8-K
Current Report

Peers (Alternatives to Fate Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Fate Therapeutics Inc News

Latest updates
Defense World32 hours ago

Fate Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-100.0%-1,6761,94493358,98044,35614,98118,54918,41417,06814,22513,41211,14215,8967,5585,4652,5152,8022,4292,8172,632
Operating Expenses6.5%52,99349,75153,22363,49887,572108,775101,372101,65892,88186,45068,84860,19157,35249,29539,04534,17237,00731,88029,54826,90123,078
  S&GA Expenses16.3%20,85517,93518,94822,62221,94321,58421,55520,35120,74216,93615,71812,16812,50010,3138,3517,5037,7296,6716,3465,2705,350
  R&D Expenses1.0%32,13831,81634,27540,87665,62987,19179,81781,30772,13969,51553,13048,02344,85238,98230,69426,66929,27825,20923,20221,63117,728
Interest Expenses------------------538400409405
Net Income-8.8%-48,004-44,122-45,170-52,755-18,881-56,363-83,563-76,105-65,690-68,621-43,308-55,133-45,089-53,099-58,684-28,072-33,520-28,302-26,609-23,478-19,760
Net Income Margin-18.1%-2.99*-2.53*-1.63*-1.77*-1.72*-2.93*-4.26*-3.72*-3.69*-3.80*-3.60*-4.42*---------
Free Cashflow9.2%-33,436-36,818-38,838-30,692-32,068-82,066-63,723-63,288-74,697-88,662-48,110-45,725-31,077--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets12.6%5705065445856307067498078589219851,0161,046622626654322302340200221
  Current Assets19.0%394332364392438502535599599633694713804494497540208227306165186
    Cash Equivalents189.8%12142.0033.0047.0042.0061.0082.0055.0065.0013412977.0010616734943383.0010025071.00183
  Net PPE-4.9%92.0097.0010210610911010910398.0092.0075.0059.0048.0032.0021.0016.0012.0011.0010.009.008.00
  Current Liabilities16.1%45.0039.0041.0045.0049.0011410492.0078.0081.0092.0010695.0086.0054.0045.0025.0028.0041.0029.0029.00
  Long Term Debt--------------------9.0011.00
    LT Debt, Current-------------------14.005.004.00
    LT Debt, Non Current--------------------9.0011.00
Shareholder's Equity15.7%426368403438477484518580633679730752790384424474219245268128146
  Retained Earnings-4.0%-1,259-1,211-1,167-1,122-1,069-1,050-994-910-834-769-700-657-602-556-503-445-417-383-355-328-305
  Additional Paid-In Capital6.7%1,6861,5801,5711,5611,5481,5361,5161,4951,4711,4491,4311,4091,392941928919636628623456451
Shares Outstanding15.4%11499.0099.0099.0098.0097.0097.0097.0096.0096.0095.0094.00---------
Float----462,000---2,340,000---6,960---2,490---1,056-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations9.0%-33.35-36.64-38.27-28.49-28.86-75.39-55.05-53.16-64.61-70.29-33.37-32.11-27.10-20.66-30.7339.00-26.67-25.53-19.84-20.31-17.49
  Share Based Compensation15.9%11.009.0010.0013.0011.0019.0019.0021.0019.0015.0014.0013.0013.009.008.007.007.005.005.004.004.00
Cashflow From Investing-61.8%17.0045.0025.0033.009.0053.0080.0040.00-7.0371.0078.00-1.37-471-166-54.1435.0024.00-11036.00-91.989.00
Cashflow From Financing53148.9%95.00-0.18-0.000.002.001.003.003.003.008.004.004385.001.002761.00-13.721621.001.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

FATE Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue$ 1,925$ 58,980
Type of Revenue [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:  
Research and development$ 32,138$ 65,629
General and administrative20,85521,943
Total operating expenses52,99387,572
Loss from operations(51,068)(28,592)
Other income (expense):  
Interest income4,1493,694
Change in fair value of stock price appreciation milestones(1,394)1,718
Other income3094,299
Total other income3,0649,711
Net loss(48,004)(18,881)
Other comprehensive income (loss):  
Unrealized gain (loss) on available-for-sale securities, net(209)1,208
Comprehensive loss$ (48,213)$ (17,673)
Net loss per common share, basic$ (0.47)$ (0.19)
Net loss per common share, diluted$ (0.47)$ (0.19)
Weighted-average common shares used to compute basic net loss per share101,104,34598,054,687
Weighted-average common shares used to compute diluted net loss per share101,104,34598,054,687

FATE Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 121,322$ 41,870
Accounts receivable8581,826
Short-term investments262,222273,305
Prepaid expenses and other current assets9,97314,539
Total current assets394,375331,540
Long-term investments7,595980
Property and equipment, net92,11696,836
Operating lease right-of-use assets60,62061,675
Restricted cash15,17715,177
Other assets99
Total assets569,892506,217
Current liabilities:  
Accounts payable6,7654,719
Accrued expenses32,04327,514
Deferred revenue159685
Operating lease liabilities, current portion6,4026,176
Total current liabilities45,36939,094
Operating lease liabilities, net of current portion95,66897,360
Stock price appreciation milestones2,7401,346
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; authorized shares - 5,000,000 at March 31, 2024 and December 31, 2023; Class A Convertible Preferred shares issued and outstanding - 2,761,108 at March 31, 2024 and December 31, 202333
Common stock, $0.001 par value; authorized shares - 250,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding - 113,798,942 at March 31, 2024 and 98,627,076 at December 31, 202311499
Additional paid-in capital1,685,9281,580,032
Accumulated other comprehensive income (loss)(194)15
Accumulated deficit(1,259,736)(1,211,732)
Total stockholders’ equity426,115368,417
Total liabilities and stockholders’ equity$ 569,892$ 506,217
FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
 CEO
 WEBSITEfatetherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES551

Fate Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Fate Therapeutics Inc? What does FATE stand for in stocks?

FATE is the stock ticker symbol of Fate Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fate Therapeutics Inc (FATE)?

As of Fri Jul 19 2024, market cap of Fate Therapeutics Inc is 487.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FATE stock?

You can check FATE's fair value in chart for subscribers.

What is the fair value of FATE stock?

You can check FATE's fair value in chart for subscribers. The fair value of Fate Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fate Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FATE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fate Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FATE is over valued or under valued. Whether Fate Therapeutics Inc is cheap or expensive depends on the assumptions which impact Fate Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FATE.

What is Fate Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, FATE's PE ratio (Price to Earnings) is -2.56 and Price to Sales (PS) ratio is 8.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FATE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fate Therapeutics Inc's stock?

In the past 10 years, Fate Therapeutics Inc has provided -0.04 (multiply by 100 for percentage) rate of return.